Baili Tianheng’s dual-antibody ADC combination therapy for advanced renal cancer has been approved for Phase II clinical trial
July 21, 2025
Source: drugdu
179
Baili Tianheng announced that it recently received the "Notice of Approval for Drug Clinical Trial" officially approved and issued by the National Medical Products Administration (NMPA). The company's independently developed innovative biological drug Iza-bren (EGFR×HER3 dual-antibody ADC) combination drug Phase II clinical trial was approved for use in a clinical trial combined with lenvatinib ± pembrolizumab to treat advanced renal cancer.
This therapy combines lenvatinib and pembrolizumab, which is expected to enhance the anti-tumor effect through multi-target synergy and fill the unmet needs in the field of renal cancer treatment. If the clinical trial goes smoothly, it will enhance the company's competitiveness in the ADC track.
https://m.cnstock.com/commonDetail/469101
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
